Fennec Pharmaceuticals Reports Preliminary Unaudited Net Rev

~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH...

Related Keywords

Oregon , United States , Robert Andrade , Lindsay Rocco , Exchange Commission , Nasdaq , Fennec Pharmaceuticals Inc , Elixir Health Public Relations , Company Expects To , Clinical Oncology Group , Drug Administration , Oregon Health , Fennec Pharmaceuticals , European Commission Marketing Authorization , Science University , Fourth Quarter , Company Expects , Audited Full Year Results , Quarter Revenue , Year End Performance , Orphan Drug Exclusivity , Pediatric Use Marketing Authorization , Annual Report , Markets ,